Sarpogrelate SR + Sarpogrelate
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Arterial Occlusive Diseases
Conditions
Arterial Occlusive Diseases, Intermittent Claudication
Trial Timeline
Nov 18, 2020 → Mar 9, 2023
NCT ID
NCT06046196About Sarpogrelate SR + Sarpogrelate
Sarpogrelate SR + Sarpogrelate is a approved stage product being developed by Yuhan for Arterial Occlusive Diseases. The current trial status is completed. This product is registered under clinical trial identifier NCT06046196. Target conditions include Arterial Occlusive Diseases, Intermittent Claudication.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06046196 | Approved | Completed |
Competing Products
20 competing products in Arterial Occlusive Diseases
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| CS1 Administration | Cereno Scientific | Phase 2 | 47 |
| CS1 | Cereno Scientific | Pre-clinical | 18 |
| Dose A KER-012 + Dose B KER-012 + Dose C KER-012 + Placebo for 24 Weeks followed by Dose B KER-012 for 72 weeks | Keros Therapeutics | Phase 2 | 44 |
| Satralizumab (Genetical Recombination) | Chugai Pharmaceutical | Phase 2 | 52 |
| edoxaban + Clopidogrel + Aspirin | Daiichi Sankyo | Phase 2 | 52 |
| tadalafil and ambrisentan upfront combination therapy | Eli Lilly | Approved | 85 |
| Tadalafil- Tablet or Oral suspension | Eli Lilly | Phase 1/2 | 41 |
| tadalafil | Eli Lilly | Pre-clinical | 23 |
| Orforglipron + Placebo | Eli Lilly | Phase 3 | 77 |
| NS-863 Low Dose + NS-863 High Dose + NS-863 Placebo | Nippon Shinyaku | Phase 2 | 52 |
| Olaparib | AstraZeneca | Phase 1/2 | 41 |
| SCH 530348 | Merck | Phase 2 | 52 |
| MK-8892 + Placebo for MK-8892 | Merck | Phase 1 | 33 |
| Riociguat | Merck | Approved | 85 |
| Sotatercept | Merck | Approved | 85 |
| Sotatercept + Background PAH Therapy | Merck | Phase 2 | 52 |
| Sotatercept + Placebo + Background PAH Therapy | Merck | Phase 3 | 77 |
| Sotatercept | Merck | Phase 3 | 77 |
| Sotatercept | Merck | Phase 3 | 77 |
| Frespaciguat + Placebo | Merck | Phase 1 | 33 |
Other Products from Yuhan
generic formulation of atorvastatin (Atorva®) + branded formulation of atorvastatin (Lipitor®)Approved
85
Pregabalin 150mg + Alpha-lipoic acid 480mg + Pregabalin 150mg + Alpha-Lipoic Acid 480mgApproved
85
Anplag Tab. 100mg bid + Anplag Tab. 100mg tidApproved
85
Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg + Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mgApproved
85
Atorvastatin 20mg loading + Atorvastatin 80mg loadingApproved
85